tirzepatide summit Another "Positive" Heart Failure Trial that Falls Short SUMMIT: Tirzepatide Reduces Cardiovascular Events

2006 Dec;52(6):421-7

Data Sources and Variables Clinical and laboratory data were extracted from the electronic medical records and entered into a de-identified study database

This is a sign that the medication is beginning to work by reducing hunger signals

In addition to its primary role in diabetes management, Ozempic offers a unique benefit for weight loss

In this phase 3b open-label, randomised, controlled trial, 751 adult participants with obesity, but without type 2 diabetes, in a 1:1 ratio received tirzepatide maximum tolerated dose (10mg or 15mg) or semaglutide maximum tolerated dose (1.7mg or 2.4mg) subcutaneously once weekly for 72 weeks

Strengths include comprehensive coverage of pharmacokinetics, safety, mechanistic insights, and health system considerations